Resveratrol Does Increase Bleeding Risk
Yes, resveratrol can cause bleeding and should be discontinued 2 weeks before surgery due to its antiplatelet effects. 1
Mechanism of Bleeding Risk
Resveratrol increases bleeding risk through multiple pathways:
- Inhibits platelet aggregation via COX pathway inhibition
- Blocks cellular calcium channels that are necessary for platelet function
- Interferes with thromboxane B2 synthesis (similar mechanism to aspirin) 1
The antiplatelet effect is dose-dependent and clinically significant at supplemental doses.
Clinical Evidence and Recommendations
Perioperative Management
The Society for Perioperative Assessment and Quality Improvement (SPAQI) 2021 consensus statement explicitly categorizes resveratrol among supplements that increase bleeding risk 1. The guideline recommends:
- Hold resveratrol for 2 weeks before surgery due to uncertain drug clearance and metabolism
- This recommendation places resveratrol in the same category as garlic, ginkgo, ginseng, and vitamin E
- The 2-week window accounts for complete elimination and restoration of normal platelet function
Drug Interactions
Resveratrol significantly enhances anticoagulant effects of warfarin through two mechanisms 2, 3:
- Inhibits CYP2C9 (the enzyme that metabolizes S-warfarin, the more potent enantiomer)
- Inhibits BCRP (breast cancer resistance protein), reducing warfarin excretion
- This combination increases warfarin exposure and INR, raising bleeding risk
In animal studies, 0.5% dietary resveratrol enhanced warfarin's anticoagulant activity despite increased CYP2C activity, demonstrating the net effect favors bleeding 2.
Important Clinical Caveats
Common pitfall: Patients may not report resveratrol use because it's marketed as a "natural" cardiovascular supplement. Specifically ask about:
- Red wine extract supplements
- Anti-aging supplements
- Cardiovascular health products
- Grape seed or Japanese knotweed extracts
Risk stratification: The bleeding risk is particularly concerning in patients who:
- Take anticoagulants (warfarin, DOACs) or antiplatelet agents (aspirin, clopidogrel)
- Have underlying coagulopathies
- Are scheduled for procedures with high bleeding risk
- Have renal or hepatic impairment (affecting resveratrol metabolism)
Strength of Evidence
The guideline recommendation 1 is based on:
- Established antiplatelet mechanisms in vitro
- Documented drug interactions with warfarin in controlled studies 2, 3
- Consensus expert opinion from anesthesiology and internal medicine specialists
- Precautionary principle given uncertain pharmacokinetics
While direct clinical bleeding events from resveratrol monotherapy are not extensively documented in humans, the mechanistic evidence and drug interaction data support treating it as a bleeding risk, particularly in the perioperative setting or when combined with other antithrombotic agents.